- GlobeNewswire•13 days ago
MIAMI, Feb. 08, 2017-- OPKO Health, Inc. today announced that its wholly owned subsidiary, OPKO Health Spain, has completed development of Enko 1, a patented intra-articular injectable hyaluronic acid ...
- GlobeNewswire•14 days ago
Enhances leadership for RAYALDEE ® with deep industry knowledge in nephrology; refocuses commercial structure on field representatives. MIAMI, Feb. 07, 2017-- OPKO Health, Inc. announced the promotion ...
- American City Business Journals•19 days ago
Opko Health (OPK) subsidiary GeneDx is set to collaborate with a nonprofit organization on human genome research. The Deciphering Developmental Disorder study, led by the Wellcome Trust Sanger Institute in partnership with GeneDx, aims to determine the clinical utility of leveraging technologies relating to human cell research to diagnose patients with developmental disorders. Through the DDD study, scientists at the Wellcome Trust Sanger Institute have worked alongside dozens of doctors over the past 4 years to analyze DNA from 13,500 patients with developmental disorders, along with their biological parents.
OPK : Summary for Opko Health, Inc. - Yahoo Finance
Opko Health, Inc. (OPK)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||8.77 x 200|
|Ask||8.85 x 100|
|Day's Range||8.62 - 8.82|
|52 Week Range||7.99 - 12.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-489.44|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|